Hypertension is the leading cause of death worldwide, affecting 1.4 billion people.
Treatment options include the widely used calcium channel blockers, among which …

Objectives Hypertension is well established as a major risk factor for cardiovascular disease.
Although there is undeniable evidence to support the beneficial effects of antihypertensive …

The database on amlodipine, a calcium antagonist of the 1, 4-dihydropyridine class, was
obtained from clinical trials in the United States, Canada, and Europe. The clinical dossier …

Amlodipine is a classical drug with varied properties extending from control of blood
pressure to as an antianginal and anti atherosclerotic agent. Amlodipine is a longer acting …

An open, non‐comparative study of 10 weeks' duration was conducted in general practice to
assess the safety of amlodipine in patients with mild to moderate hypertension. Of the 5352 …

Background: Systolic hypertension is the most common form of hypertension, particularly in
people aged> 60 years. Caused by decreased compliance of large arteries, systolic …

A multicenter, placebo-controlled trial assessed the antihypertensive efficacy and safety of
different doses of amlodipine in patients with mild to moderate hypertension. Amlodipine …

Three hundred and twenty hypertensive out-patients were recruited to this multicentre
general practice study of the efficacy and safety of amlodipine. Patients with baseline sitting …

Background: This study set out to assess the safety and efficacy of amlodipine in two cohorts
of patients who were attended in primary-and specialised-care centres, respectively …

Once-daily administration of amlodipine, a long-acting dihydropyridine calcium-channel
blocker, and atenolol, a cardioselective [beta]-adrenoceptor blocking agent, were compared …